Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful ...

King of Prussia, Pennsylvania Monday, September 16, 2024, 17:00 Hrs [IST] ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

CSL and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare has granted approval for ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season.

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Japan’s Ministry of Health, Labor and Welfare recently granted approval for CSL and Arcturus Therapeutics’ self-amplifying ...

The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing ...